Search research articles
Contact Us
Filters
Showing results (11-20 of 64) with videos related to
Page
of 7
Sort By:
Cancer Detection and Prevention
|
January 1, 1991
Large-scale production of human tumorcytotoxic macrophages grown from blood monocytes of cancer patients
W Brugger, C Scheibenbogen, S Krause, et al.
The Journal of Allergy and Clinical Immunology
|
October 1, 1988
Effects of SO2 exposure on allergic sensitization in the guinea pig
F Riedel, M Krämer, C Scheibenbogen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 1, 1996
A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma
T M Proebstle, C Scheibenbogen, W Sterry, et al.
International Journal of Cancer
|
February 6, 1999
Induction of tyrosinase-reactive T cells by treatment with dacarbazine, cisplatin, interferon-alpha +/- interleukin-2 in patients with metastatic melanoma
A Schmittel, U Keilholz, R Max, et al.
Melanoma Research
|
June 1, 1995
Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load
C Scheibenbogen, T Möhler, J Haefele, et al.
Melanoma Research
|
August 1, 1996
Regulation of interleukin-8 mRNA expression and protein secretion in a melanoma cell line by tumour necrosis factor-alpha and interferon-gamma
T Möhler, C Scheibenbogen, J Häfele, et al.
Research in Immunology
|
January 1, 1992
The interleukin-2 receptor in human monocytes and macrophages: regulation of expression and release of the alpha and beta chains (p55 and p75)
C Scheibenbogen, U Keilholz, M Richter, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1994
Immunotherapy of metastatic melanoma with interferon-alpha and interleukin-2: pattern of progression in responders and patients with stable disease with or without resection of residual lesions
U Keilholz, C Scheibenbogen, E Stoelben, et al.
Melanoma Research
|
April 1, 1996
Prognostic factors for response and survival in patients with metastatic melanoma receiving immunotherapy
U Keilholz, C Scheibenbogen, M Sommer, et al.
Melanoma Research
|
January 26, 1999
Long-term outcome of treatment with dacarbazine, cisplatin, interferon-alpha and intravenous high dose interleukin-2 in poor risk melanoma patients
T M Proebstle, T Fuchs, C Scheibenbogen, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 64) with videos related to
Sort By:
Page
of 7
Cancer Detection and Prevention
|
January 1, 1991
Large-scale production of human tumorcytotoxic macrophages grown from blood monocytes of cancer patients
W Brugger, C Scheibenbogen, S Krause, et al.
The Journal of Allergy and Clinical Immunology
|
October 1, 1988
Effects of SO2 exposure on allergic sensitization in the guinea pig
F Riedel, M Krämer, C Scheibenbogen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 1, 1996
A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma
T M Proebstle, C Scheibenbogen, W Sterry, et al.
International Journal of Cancer
|
February 6, 1999
Induction of tyrosinase-reactive T cells by treatment with dacarbazine, cisplatin, interferon-alpha +/- interleukin-2 in patients with metastatic melanoma
A Schmittel, U Keilholz, R Max, et al.
Melanoma Research
|
June 1, 1995
Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load
C Scheibenbogen, T Möhler, J Haefele, et al.
Melanoma Research
|
August 1, 1996
Regulation of interleukin-8 mRNA expression and protein secretion in a melanoma cell line by tumour necrosis factor-alpha and interferon-gamma
T Möhler, C Scheibenbogen, J Häfele, et al.
Research in Immunology
|
January 1, 1992
The interleukin-2 receptor in human monocytes and macrophages: regulation of expression and release of the alpha and beta chains (p55 and p75)
C Scheibenbogen, U Keilholz, M Richter, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1994
Immunotherapy of metastatic melanoma with interferon-alpha and interleukin-2: pattern of progression in responders and patients with stable disease with or without resection of residual lesions
U Keilholz, C Scheibenbogen, E Stoelben, et al.
Melanoma Research
|
April 1, 1996
Prognostic factors for response and survival in patients with metastatic melanoma receiving immunotherapy
U Keilholz, C Scheibenbogen, M Sommer, et al.
Melanoma Research
|
January 26, 1999
Long-term outcome of treatment with dacarbazine, cisplatin, interferon-alpha and intravenous high dose interleukin-2 in poor risk melanoma patients
T M Proebstle, T Fuchs, C Scheibenbogen, et al.
Page
of 7